A Phase I/II Study of Cabozantinib (XL184) in Patients with Recurrent or Persistent Myeloma

Full Title

A Phase I/II Trial of Cabozantinib (XL184) in Patients with Relapsed or Refractory Myeloma Back to top

Purpose

Cabozantinib (XL184) is an investigational drug that blocks several proteins (called MET, RET, and vascular endothelial growth factor receptor 2) that help keep cancer cells alive, including myeloma cells. It works differently than other drugs approved for treating multiple myeloma. It is a capsule that is taken orally (by mouth).

In this study, researchers are assessing the safety and effectiveness of cabozantinib in patients with multiple myeloma that has returned after or continued to grow despite previous treatment.

Back to top

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has returned after or continued to grow despite previous treatment.
  • Prior treatment should have included at least one immunomodulating drug (such as lenalidomide or thalidomide) and at least one proteasome inhibitor (such as bortezomib).
  • At least 2 weeks must have passed since completion of prior therapies, and patients must have recovered from any serious side effects.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Sergio Giralt at 212-639-6009.

Back to top

Protocol

12-240

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators